Asceneuron halts Alzheimer’s trial adding to tau-targeting setbacks
After Eli Lilly and Biogen’s setbacks in developing O-GlaNAcase (OGA) inhibitors for Alzheimer’s disease, Asceneuron has now halted its own …
Post
-
-
WuXi Biologics introduces E coli expression system
WuXi Biologics has launched the E coli expression system, EffiX, designed to enhance the production of recombinant proteins and plasmid DNA …
-
MWC Barcelona 2025: Maximizing 5G network value in the age of AI
Li predicts that symbiosis between 5G-A and AI technologies will stimulate double-digit growth in both DOU (data of usage) and …
-
FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancer
The US Food and Drug Administration (FDA) has approved BeiGene’s Tevimbra (tislelizumab-jsgr) along with platinum-containing chemotherapy as first-line treatment for …
-
Antibody drug conjugates: Tackling the unsolved challenges with novel technologies
Antibody drug conjugates (ADCs) represent a promising new generation of cancer therapeutics and a significant advance in targeted drug delivery. …
-
Asceneuron halts Alzheimer’s trial adding to tau-targeting setbacks
After Eli Lilly and Biogen’s setbacks in developing O-GlaNAcase (OGA) inhibitors for Alzheimer’s disease, Asceneuron has now halted its own …
-
WuXi Biologics introduces E coli expression system
WuXi Biologics has launched the E coli expression system, EffiX, designed to enhance the production of recombinant proteins and plasmid DNA …
-
MWC Barcelona 2025: Maximizing 5G network value in the age of AI
Li predicts that symbiosis between 5G-A and AI technologies will stimulate double-digit growth in both DOU (data of usage) and …
-
FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancer
The US Food and Drug Administration (FDA) has approved BeiGene’s Tevimbra (tislelizumab-jsgr) along with platinum-containing chemotherapy as first-line treatment for …
-
Antibody drug conjugates: Tackling the unsolved challenges with novel technologies
Antibody drug conjugates (ADCs) represent a promising new generation of cancer therapeutics and a significant advance in targeted drug delivery. …
-
Callio raises $187m for proof-of-concept for dual-payload ADC
Callio Therapeutics has raised $187m in a Series A financing round to achieve clinical proof-of-concept for its human epidermal growth …
-
Are European biopharma manufacturers ‘nearshoring’?
In step with international news in recent times, European pharma and biotech are leaning towards ‘nearshoring’, preferring domestic operations to …
-
Machine learning adoption into supply chain management on the horizon
Widespread integration of machine learning (ML) into supply chain management by major pharma suppliers is just a few years away, …
-
Reflecting on a milestone year for cell and gene therapies
The previous 12 months have seen considerable progress in cell and gene therapies, with the first solid tumor products receiving …
-
Genentech wins FDA approval for second stroke treatment
Genentech has secured a second marketed stroke therapy after the US Food and Drug Administration (FDA) approved a label expansion …
